Comparable
COVID
‐19 outcomes with current use of
GLP
‐1 receptor agonists,
DPP
‐4 inhibitors or
SGLT
‐2 inhibitors among patients with diabetes who tested positive for
SARS‐CoV
‐2
Comparable
COVID
‐19 outcomes with current use of
GLP
‐1 receptor agonists,
DPP
‐4 inhibitors or
SGLT
‐2 inhibitors among patients with diabetes who tested positive for
SARS‐CoV
‐2
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started